Cumberland Pharmaceuticals Inc. [CPIX] shares are down more than -37.79% this year and recently increased 0.01% or $0.02 to settle at $3.00. Analysts expect CPIX to grow earnings at a 30.00% annual rate over the next 5 years. CPIX has a short ratio of 5.05. This implies that the market is currently less bullish on the outlook for CPIX.
On 17, November 2020, Introducing RediTrex®, A New Methotrexate Delivery System. According to news published on Yahoo Finance, Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announced today the launch of RediTrex® (methotrexate) injection. RediTrex is a new line of pre-filled syringes specifically designed for ease of handling and dosing accuracy for the subcutaneous administration of methotrexate in patients with arthritis and psoriasis.
Analyst Birdseye View:
The most recent analyst activity for Cumberland Pharmaceuticals Inc. [NASDAQ:CPIX] stock was on February 01, 2011, when it was Reiterated with a Neutral rating from UBS, which also lowered its 12-month price target on the stock from $8 to $6.50. Before that, on November 12, 2012, UBS Recapitulated a Neutral rating and elevated its amount target to $5. On December 16, 2010, UBS Downgrade a Neutral rating and plunged its price target on this stock from $10 to $8. On August 17, 2010, UBS Reiterated a Buy rating and decreased its price target from $11 to $10. On August 17, 2010, Morgan Joseph Reiterated a Buy rating and decreased its price target to $10. On August 17, 2010, Jefferies Downgrade a Hold rating and boosted its amount target on this stock to $5.50. On May 14, 2010, Morgan Joseph Reiterated a Buy rating and decreased its target amount on this stock from $21 to $15.
In the past 52 weeks of trading, this stock has oscillated between a low of $2.77 and a peak of $5.52. Right now, according to Wall Street analyst the average 12-month amount target is $8.50. At the most recent market close, shares of Cumberland Pharmaceuticals Inc. [NASDAQ:CPIX] were valued at $3.00.
Cumberland Pharmaceuticals Inc. [NASDAQ:CPIX] most recently reported quarterly sales of 9.25 billion, which represented growth of 34.80%. This publicly-traded organization’s revenue is $505,677 per employee, while its income is -$37,636 per employee. This company’s Gross Margin is currently 76.50%, its Operating Margin is -13.70%, its Pretax Margin is -7.63, and its Net Margin is -7.44. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -3.21, -6.61, -5.98 and -4.80 respectively.
The Principal structure of this organization shows its whole liability to whole principal at 29.60 and the whole liability to whole assets at 20.31. It shows enduring liability to the whole principal at 28.33 and enduring liability to assets at 0.19 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 2.93 points at 1st support level, the second support level is making up to 2.88. But as of 1st resistance point, this stock is sitting at 3.03 and at 3.07 for 2nd resistance point.
Cumberland Pharmaceuticals Inc. [CPIX] reported its earnings at $0.02 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.07/share signifying the difference of 0.09 and 128.60% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.01 calling estimates for $0.03/share with the difference of -0.04 depicting the surprise of -133.30%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Cumberland Pharmaceuticals Inc. [NASDAQ:CPIX] is 2.00. Likewise, the Quick ratio is also the same, showing Cash ratio at 1.17. Now if looking for a valuation of this stock’s amount to sales ratio it’s 1.67 and it’s amount to book ratio is 1.54.
The most recent insider trade was by Galante Joseph C, Director, and it was the purchase of 225.0 shares on Aug 26. Galante Joseph C, the Director, completed a purchase of 375.0 shares on Aug 21. On Aug 14, Galante Joseph C, Director, completed a purchase of 375.0 shares.